Placebo controlled,randomised,crossover study of the efficacy of dipyridamole in the management of angina in patients with Coronary Slow Flow Phenomenon
Placebo controlled, randomised, crossover study of the efficacy of dipyridamole in reducing the number of angina episodes in patients with Coronary Slow Flow Phenomenon (CSFP)
The Queen Elizabeth Hospital,Cardiology Unit
16 participants
Oct 1, 2002
Interventional
Conditions
Summary
To assess if dipyridamole reduces the frequency of angina in patient with CSFP. Study pharmacist was the only person unblinded to study treatment. Blinding was achieved by using pre numbered study drug containers and by fax randomisation to study pharmacist who would then allocate the study drug to the patient who is also blinded
Eligibility
Inclusion Criteria1
- Coronary slow flow phenomenon. Frequent angina(> 3 episodes per week).
Exclusion Criteria1
- Significant haemorrhagic risk.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Dipyridamole 200mgs orally twice daily for 10 weeks ie 5 weeks of each treatment blinded.After 5 weeks of treatment patients would cross over to opposite treatment.Patients and study staff(excluding study pharmacist) remain blinded to the study drug throughout the duration of the study.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12606000236594